Arexvy is GSK’s adjuvanted recombinant vaccine designed to prevent lower respiratory tract disease (LRTD) caused by RSV. Initially approved for adults aged 60 and older, as well as those aged 50-59 ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

Investing.com -- GSK plc (LSE:GSK) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication of its RSV ...

EMA committee recommends approval of GSK’s RSV vaccine, Arexvy for all adults 18 years and older: London, UK Saturday, December 13, 2025, 13:00 Hrs [IST] GSK plc announced that ...

GSK said on Friday a panel ‍of the European Medicines Agency had backed the use of its ‌respiratory syncytial ‌virus (RSV) ...

GSK said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended ...

Arexvy targets recombinant respiratory syncytial virus, a contagious disease which affects the lungs, and is diagnosed in roughly 64 million people annually, according to research cited by GSK. The ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ — According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) ...